I think it’s a really, really good question and it’s so topical right now. Speaking to colleagues, the adjuvant discussion in clinic is probably the most difficult conversation that we have. I think before a patient comes into the clinic, we look at the pathology and the imaging and we may already have a feel for whether we think that patient should have adjuvant therapy...
I think it’s a really, really good question and it’s so topical right now. Speaking to colleagues, the adjuvant discussion in clinic is probably the most difficult conversation that we have. I think before a patient comes into the clinic, we look at the pathology and the imaging and we may already have a feel for whether we think that patient should have adjuvant therapy. But it’s not until the patient actually sits down in front of you that you can get a feeling for what is in their interest and what is best for them. There are some patients that want to do everything they possibly can to reduce the risk of recurrence, whereas others are much more aware of the risks and the toxicity. And I think what we’ve shown through our study is that that initial counselling and education meeting is so vital and we need to make sure that our patients are very well informed about the potential long-term toxicity. We as clinicians are very good at talking about the acute severe side effects, but often it’s those milder grade one to two side effects that are still lingering at two years that may be more impactful on these cured patients in the long term.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
